#ESMO24 A summary of presentations that caught my eye: - STX-478 inhibitor in PIK3CA mutant tumors - BMS-986365 AR degrader/antagonist in mCRPC - BNT327 PD-L1/VEGF in EGFR-mutated NSCLC - NVL-655 inhibitor in ALK-mutated NSCLC - Ponsegromab anti-GDF15 for cancer patients with cachexia